Advertisement

Topics

Once-daily netarsudil generally safe, with minimal treatment-related adverse events

13:12 EDT 16 Apr 2018 | Healio

Inder Paul Singh
WASHINGTON — Once-daily netarsudil for patients with ocular hypertension or open-angle glaucoma was safe, with mild conjunctival hyperemia being the most frequently occurring ocular adverse event, according to a speaker here.
In a pooled analysis of four phase 3 trials comparing once-daily Rhopressa (netarsudil ophthalmic solution 0.02%, Aerie Pharmaceuticals) with twice-daily timolol, netarsudil had limited ocular adverse events and effects on heart rate change from baseline and was “generally safe and well tolerated,” Inder Paul Singh, MD, said at the

Original Article: Once-daily netarsudil generally safe, with minimal treatment-related adverse events

NEXT ARTICLE

More From BioPortfolio on "Once-daily netarsudil generally safe, with minimal treatment-related adverse events"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Adempas (riociguat)
The United States Food and Drug Administration (FDA) has approved on October 8th 2013 Adempas® (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after ...

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...